Interfaith Center on Corporate Responsibility - new report on pharmaceutical firms' responses to AIDS

In August 2006, the Interfaith Center on Corporate Responsibility (ICCR) issued a report, "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets".  A PowerPoint summary of the report, which includes scores and "bottom line" assessment of each company, is available here.  The Business & Human Rights Resource Centre invited the 15 benchmarked companies to respond to the report; the results to date are indicated below.  Below the companies' responses are rejoinders by ICCR and Physicians for Social Justice (Nigeria) to the companies' responses, and a November 2006 follow-up report by ICCR.

COMPANY RESPONSES / NON-RESPONSES:

Abbott Laboratories statement [DOC]

AstraZeneca response [DOC]

Boehringer-Ingelheim response [DOC]

Bristol-Myers Squibb response [DOC]

Eli Lilly - declined to respond

Gilead Sciences - declined to respond

GlaxoSmithKline response [DOC]

Hoffman-La Roche - declined to respond

Merck response [PDF]

Novartis response [DOC]

Pfizer response [PDF]

sanofi-aventis - declined to respond

Schering-Plough - declined to respond

Tibotec (part of Johnson & Johnson) response [DOC]

Wyeth - press release sent in response to ICCR report

REJOINDERS:

ICCR statement regarding the company responses (6 Nov 2006) [DOC]

Physicians for Social Justice (Nigeria) rejoinder to the company responses [DOC]
Novartis response to Physicians for Social Justice [DOC]

NOV 2006 ICCR UPDATE:

Benchmarking AIDS: 2006 Year End Update [PDF]
- includes recent steps taken by Abbott, Gilead, GlaxoSmithKline, Novartis, Roche & recommendations for next steps for each of these companies

Get RSS feed of these results

All components of this story

Company response
23 August 2006

Response by Novartis: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Novartis - finds none has comprehensive approach.

Read the full post here

Company response
23 August 2006

Response by Pfizer: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Pfizer - finds none has comprehensive approach.

Read the full post here

Article
17 August 2006

International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

Author: Daniel Rosan, Program Director for Public Health, Interfaith Center on Corporate Responsibility [USA]

[Presentation by Daniel Rosan begins at 54:30; refers to Abbott Laboratories, Bristol-Myers Squibb, Merck, Gilead Sciences, Wyeth]

Read the full post here

Article
17 August 2006

[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

Author: Daniel Rosan, Program Director for Public Health, Interfaith Center on Corporate Responsibility [USA]

[identifies pharmaceutical best practice in key areas including research, paediatric needs, drug accessibility, reporting, philanthropy, political engagement; rates 15 top pharmaceutical firms on each practice: Abbott Laboratories, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences, Johnson & Johnson, Eli Lilly, Merck, Novartis, Pfizer, Hoffmann-La Roche (part of Roche), sanofi-aventis, Schering-Plough, Wyeth]

🚫Read the full post here

Article
14 August 2006

New Report: Top pharma companies fail to address industry best practices on HIV/AIDS

Author: Interfaith Center on Corporate Responsibility [USA]

The Interfaith Center on Corporate Responsibility released a comprehensive scorecard evaluating the pharmaceutical industry's efforts in the fight against HIV/AIDS...The ICCR report highlights the large disparities between industry best practices in addressing...HIV/AIDS...and the current actions of 15 leading pharmaceutical companies. "We see two major problems - a failure to develop new medicines that address neglected diseases and a lack of access for poor patients to the existing medicines," said Daniel Rosan, ICCR's Program Director for Public Health and author of the report... [companies rated: Abbott Laboratories, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences, Johnson & Johnson, Eli Lilly, Merck, Novartis, Pfizer, Hoffmann-La Roche (part of Roche), sanofi-aventis, Schering-Plough, Wyeth]

🚫Read the full post here

Company non-response
1 August 2006

Sanofi-Aventis did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including sanofi-aventis - finds none has comprehensive approach.

Company non-response
1 August 2006

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Company non-response
8 January 2006

Gilead Sciences did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Gilead - finds none has comprehensive approach.

Company non-response
8 January 2006

Hoffmann-La Roche (part of Roche) did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Hoffman-La Roche - finds none has comprehensive approach.